Cardinal Health Shares Rise Following Q4 Earnings and Optimistic Fiscal 2027 Projections

2026-08-12

The BareStory

Cardinal Health reported its fourth-quarter financial results for fiscal 2026 on Tuesday, posting a revenue increase of nearly 6% year-over-year to $63.67 billion. Although this fell short of the projected $65.03 billion, the company's adjusted earnings per share (EPS) of $2.60 beat the consensus estimate of $2.42. Following the report, the company's shares rose over 1% to set a new record close on Tuesday, reaching an intraday high of $258.30.

Company executives attributed the performance to varied segment drivers. Chief Financial Officer Aaron Alt stated that revenue in the Pharmaceutical and Specialty Solutions segment grew 6% to $58.85 billion, boosted by GLP-1 drug sales but tempered by lower drug prices stemming from Medicare negotiations. Additionally, the Global Medical Products and Distribution segment recorded $3.13 billion in revenue, which included a $100 million profit benefit from tariff refunds following a Supreme Court decision.

For fiscal 2027, Cardinal Health projected adjusted earnings growth of 13% to 15%, translating to $12.40 to $12.60 per share, which is higher than the consensus estimate of $12.04. The company also expects to generate free cash flow between $3.5 billion and $4 billion. Following the release of this fiscal 2027 guidance, several financial institutions raised their price targets for the company, with Wells Fargo increasing its target to $277 and Citi raising its target to $280.

Left Perspective

Curbing Monopolistic Price Extraction
Exposing Windfall Profit Arbitrage
Resisting Shareholder Value Distortions

Right Perspective

Fueling Efficient Capital Allocation
Confronting Distortive Price Controls
Securing Regulatory Policy Stability

Left Perspective

• Curbing Monopolistic Price Extraction Social equity dictates that life-saving medicine must remain affordable, making government-led interventions like Medicare drug negotiations a critical tool for public welfare. Cardinal Health’s lower drug prices in its pharmaceutical segment demonstrate that public policy can successfully intervene to cap corporate healthcare revenues in favor of consumer savings. The fact that the company still managed an adjusted EPS beat of $2.60 and a record stock close of $258.30 proves that public cost-containment measures do not threaten corporate viability.

• Exposing Windfall Profit Arbitrage Public accountability requires scrutinizing how corporate giants inflate their bottom lines through judicial decisions rather than genuine value creation. Cardinal's $100 million profit boost from Supreme Court-ordered tariff refunds highlights how legal technicalities can subsidize private balance sheets. When corporations capture massive financial gains from tariff rollbacks while projecting up to $4 billion in free cash flow, those resources should ideally benefit the broader healthcare ecosystem rather than merely enriching institutional investors.

• Resisting Shareholder Value Distortions Prioritizing Wall Street projections risks widening the gap between corporate prosperity and actual public health outcomes. The surging price targets from major financial institutions like Wells Fargo and Citi prioritize shareholder payouts over affordable care access. As Cardinal Health projects a massive 13% to 15% earnings growth for fiscal 2027, this aggressive capital accumulation suggests that the financialization of healthcare continues to extract wealth from patients to benefit market elites.

Right Perspective

• Fueling Efficient Capital Allocation Long-term economic prosperity depends on rewarding operational efficiency and allowing market demand to dictate capital allocation. Cardinal Health's adjusted EPS beat of $2.60 and rising share price show that market-driven demands, such as the surging popularity of GLP-1 drugs, are the true engines of healthcare sector growth. When companies successfully optimize their distribution networks to meet these consumer needs, they generate the robust revenues necessary to sustain a reliable national medical supply chain.

• Confronting Distortive Price Controls Fiscal discipline and market efficiency are severely compromised when state interventions artificially suppress natural pricing structures. The Medicare price negotiations, which tempered Cardinal's revenue growth despite high demand, serve as a stark warning about the dampening effects of government price controls. Suppressing revenue through regulatory fiat threatens the long-term investment capacity of critical distributors, potentially starving the healthcare sector of the capital needed to handle future distribution challenges.

• Securing Regulatory Policy Stability Protecting the rule of law and ensuring predictable regulatory environments are foundational to maintaining investor confidence and corporate stability. The Supreme Court's decision resulting in a $100 million tariff refund for Cardinal Health underscores the necessity of checking executive agency overreach to maintain market order. By returning these funds, the legal system enables Cardinal to project up to $4 billion in free cash flow, providing the financial security needed to reinvest in national logistics networks and driving elevated price targets of up to $280.

How it may affect me

As a U.S. reader:

• You may experience lower prices on certain prescription medications in the short term due to the ongoing impact of Medicare drug negotiations on pharmaceutical distribution.

• If you rely on high-demand treatments such as GLP-1 drugs, you may benefit from more reliable access as distributors optimize their networks to satisfy consumer demand.

• In the long term, you could benefit from a more stable national medical logistics network funded by the company's projected free cash flow and recent tariff refunds, though these financial gains may alternatively be directed toward institutional investors rather than directly lowering your healthcare costs.

• You could face potential future risks of healthcare supply chain disruptions if government price regulations ultimately restrict the capital that private distributors have available to reinvest in distribution infrastructure.

Cardinal Health Shares Rise Following Q4 Earnings and Optimistic Fiscal 2027 Projections

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at